|
Dec 28 |
PDS Biotech Reports Median Overall Survival (OS) of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaini...
Median OS of 21 months in 29 checkpoint... |
|
Dec 15 |
PDS Biotech Completes First Stage of Enrollment in Checkpoint Inhibitor Refractory Arm of Phase 2 Clinical Trial in Adva...
VERSATILE-002 Phase 2 study investigating... |
|
Nov 21 |
PDS Biotech Executives to Present an Overview of Oncology and Infectious Disease Programs at the World Vaccine & Immunot...
Chief Medical Officer, Dr. Lauren V. Wood, to... |
|
Nov 14 |
PDS Biotech Reports Third Quarter 2022 Financial Results and Provides Business Update...
Announced preliminary PDS0101 efficacy and... |
|
Nov 14 |
PDS Biotech Announces 100% Clinical Response in Cervical Cancer Patients in Preliminary Data from IMMUNOCERV Phase 2 Cli...
In the trial studying the combination of PDS0101... |
|
Nov 07 |
PDS Biotech Announces Presentation of Preliminary PDS0101 Efficacy, Safety, and Immunology Data at Society for Immunothe...
Patients with high-risk, locally advanced... |
|
Oct 31 |
PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2022 Financial Results...
FLORHAM PARK, N.J., Oct. 31, 2022 (GLOBE... |
|
Oct 27 |
PDS Biotech Provides Highlights from Head and Neck Cancer KOL Roundtable...
Jared Weiss, MD, Lead Investigator for the... |
|
Oct 25 |
PDS Biotech Chief Medical Officer Dr. Lauren V. Wood to Address 2022 International Head and Neck Conference...
Conference to focus upon improving patient... |
|
Oct 19 |
PDS Biotech to Present at the LD Micro Main Event XV...
FLORHAM PARK, N.J., Oct. 19, 2022 (GLOBE... |
|
Oct 17 |
PDS Biotech Announces Abstract Demonstrating Versatility of the Versamune® Platform in Oncology Accepted for Presentati...
Abstract highlights foundational research in the... |
|
Oct 12 |
PDS Biotech to Host Head and Neck Cancer KOL Roundtable on October 26, 2022...
FLORHAM PARK, N.J., Oct. 12, 2022 (GLOBE... |
|
Oct 11 |
PDS Biotech Announces Expanded Interim Data in PDS0101 Triple Combination Phase 2 Trial Targeting Advanced HPV-Positive ...
66% of HPV 16-positive checkpoint inhibitor... |
|
Oct 07 |
PDS Biotech Reports An Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)...
FLORHAM PARK, N.J., Oct. 07, 2022 (GLOBE... |
|
Oct 05 |
PDS Biotech Announces Abstracts Involving Research of PDS0101 Accepted for Presentation at SITC 2022...
Abstracts highlight data from Phase 2 clinical trials... |
|
Oct 03 |
PDS Biotech Announces Successful End-of-Phase 2 Meeting With the FDA and Preparation for the Registrational Trial of PDS...
FLORHAM PARK, N.J., Oct. 03, 2022 (GLOBE... |
|
Sep 23 |
PDS Biotech Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
FLORHAM PARK, N.J., Sept. 23, 2022 (GLOBE... |
|
Sep 22 |
PDS Biotech to Participate at Cantor Fitzgerald’s Oncology & HemOnc Conference...
FLORHAM PARK, N.J., Sept. 22, 2022 (GLOBE... |
|
Sep 21 |
PDS Biotech and National Cancer Institute Identify Optimal Patient Group for Advancing PDS0101-Based Triple Combination ...
Ongoing program to focus on checkpoint inhibitor... |
|
Sep 06 |
PDS Biotech to Participate at H.C. Wainwright 24th Annual Global Investment Conference...
FLORHAM PARK, N.J., Sept. 06, 2022 (GLOBE... |
|
Aug 24 |
PDS Biotech Completes $35 Million Financing Agreement Led By Horizon Technology Finance...
Initial tranche of $25 million provides funding in... |
|
Aug 08 |
PDS Biotech Reports Second Quarter 2022 Financial Results and Provides Business Update...
Announced results from two of the ongoing Phase 2... |
|
Aug 04 |
PDS Biotech Independent Data Monitoring Committee Recommends VERSATILE-002 Trial Continuation without Modifications...
Safety evaluation of 43 patients with no grade 3 or... |
|
Aug 02 |
PDS Biotech to Participate at BTIG Biotechnology Conference 2022...
FLORHAM PARK, N.J., Aug. 02, 2022 (GLOBE... |
|
Jul 26 |
PDS Biotechnology Announces Conference Call and Webcast for Second Quarter 2022 Financial Results...
FLORHAM PARK, N.J., July 26, 2022 (GLOBE... |
|
Jul 14 |
PDS Biotechnology Announces Presentation of Universal Flu Vaccine Preclinical Data at the 41st American Society of Virol...
PDS0202 neutralized multiple strains of... |
|
Jun 03 |
PDS Biotechnology Appoints Spencer Brown as Senior Vice President, General Counsel...
Reports An Inducement Grant Under NASDAQ Listing... |
|
Jun 02 |
PDS Biotechnology Granted FDA Fast Track Designation for Lead Candidate PDS0101...
PDS Biotech has been granted Fast Track... |
|
May 31 |
PDS Biotech Announces Expansion of its VERSATILE-002 Clinical Trial into Europe...
Promising preliminary clinical results validate... |
|
May 26 |
PDS Biotech Announces Presentation of Efficacy and Safety Data from VERSATILE-002 Phase 2 Clinical Trial in Recurrent or...
Preliminary data from first 19 patients treated with... |
|
May 26 |
PDS Biotech Announces Presentation of Data from NCI-Led Triple Combination Phase 2 Clinical Trial in Advanced, Refractor...
77% of checkpoint inhibitor (CPI) refractory... |
|
May 25 |
PDS Biotechnology to Host Conference Call Following Poster Presentations of PDS0101 Data at 2022 ASCO Annual Meeting...
Conference Call on Tuesday, June 7, 2022 at 8:00... |
|
May 18 |
PDS Biotechnology Appoints Seasoned Business Development Executive Sanjay Zaveri as Senior Vice President, Business Deve...
Reports An Inducement Grant Under NASDAQ Listing... |
|
May 17 |
PDS Biotech to Participate at Upcoming Investor Conferences...
FLORHAM PARK, N.J., May 17, 2022 (GLOBE... |
|
May 11 |
PDS Biotech Provides Business Update and Reports First Quarter 2022 Financial Results...
Company to host conference call and webcast... |
|
Apr 28 |
PDS Biotechnology Announces Conference Call and Webcast for First Quarter 2022 Financial Results...
FLORHAM PARK, N.J., April 28, 2022 (GLOBE... |
|
Apr 27 |
PDS Biotech Announces Two Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology Annual M...
Preliminary efficacy and safety update on... |
|
Apr 20 |
PDS Biotech Chief Medical Officer, Lauren V. Wood, to Chair Session at the World Vaccine Congress...
FLORHAM PARK, N.J., April 20, 2022 (GLOBE... |
|
Apr 19 |
PDS Biotech Receives $1.2 Million After Selling Its Net Operating Loss Tax Benefits Through The New Jersey Economic Deve...
FLORHAM PARK, N.J., April 19, 2022 (GLOBE... |
|
Apr 08 |
PDS Biotechnology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)...
FLORHAM PARK, N.J., April 08, 2022 (GLOBE... |
|
Mar 31 |
PDS Biotech Provides Business Update and Reports Fourth-Quarter and Full-Year 2021 Financial Results...
Company to host conference call and webcast... |
|
Mar 22 |
PDS Biotechnology Reschedules 2021 Fourth Quarter and Full Year Financial Results and Conference Call...
FLORHAM PARK, N.J., March 22, 2022 (GLOBE... |
|
Mar 15 |
PDS Biotech Announces Achievement of an Enrollment Objective in National Cancer Institute-Led Phase 2 Clinical Trial of ...
NCI achieves the enrollment objective of thirty... |
|
Mar 09 |
PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter and Full Year 2021 Financial Results...
FLORHAM PARK, N.J., March 09, 2022 (GLOBE... |
|
Mar 01 |
PDS Biotechnology to Present at the 32nd Oppenheimer Annual Healthcare Conference...
FLORHAM PARK, N.J., March 01, 2022 (GLOBE... |
|
Feb 24 |
PDS Biotech Announces Preliminary Safety Data on PDS0101 in Combination With KEYTRUDA® (pembrolizumab) at the 2022 Mult...
Preliminary safety data has shown that PDS0101 in... |
|
Feb 15 |
PDS Biotech Announces Clinical Trial with Mayo Clinic to Study PDS0101 in Early Stage Pre-Metastatic- HPV-Associated Hea...
The study evaluates PDS0101 with and without... |
|
Feb 02 |
PDS Biotech Announces Preliminary Efficacy Achievement in VERSATILE-002 Phase 2 Trial of PDS0101 in Combination With KEY...
Achievement of initial efficacy milestone allows... |
|
Jan 27 |
PDS Biotech Announces Preclinical Data for PDS0202 Universal Influenza Vaccine...
PDS0202 (Infectimune™ + COBRA Influenza... |
|
Jan 18 |
PDS Biotechnology to Present at B. Riley Securities Virtual Oncology Conference...
FLORHAM PARK, N.J., Jan. 18, 2022 (GLOBE... |
|
Jan 12 |
PDS Biotech Announces Presentation of PDS0101 Data at the 2022 Multidisciplinary Head and Neck Cancers Symposium...
FLORHAM PARK, N.J., Jan. 12, 2022 (GLOBE... |
|
Jan 10 |
PDS Biotech Granted Patent for its Novel HPV16 Immunotherapy...
Extends patent protection of PDS0101 by the... |
|
Jan 05 |
PDS Biotechnology to Present at H.C. Wainwright Bioconnect Virtual Conference...
FLORHAM PARK, N.J., Jan. 05, 2022 (GLOBE... |
